Government-Owned Inventions; Availability for Licensing, 13460 [2017-04834]
Download as PDF
13460
Federal Register / Vol. 82, No. 47 / Monday, March 13, 2017 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Mary Custer, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4148,
MSC 7850, Bethesda, MD 20892, (301) 435–
1164, custerm@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR Panel:
Neural Regulation of Cancer.
Date: March 29, 2017.
Time: 12:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Rolf Jakobi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7806, Bethesda, MD 20892, 301–495–
1718, jakobir@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR 16–
218: Provocative Questions in Pediatric
Cancer.
Date: April 4, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Charles Morrow, MD,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
MSC 7804, Bethesda, MD 20892, 301–451–
4467, morrowcs@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
N6, A Novel, Broad, Highly Potent HIVSpecific Antibody
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Description of Technology
The N6 antibody has evolved a
unique mode of binding that depends
less on a variable area of the HIV
envelope known as the V5 region and
focuses more on conserved regions,
which change relatively little among
HIV strains. This allows N6 to tolerate
changes in the HIV envelope, including
the attachment of sugars in the V5
region, a major mechanism by which
HIV develops resistance to other VRC01class antibodies. N6 was shown in preclinical studies to neutralize
approximately 98 percent of HIV
isolates tested. The studies also
demonstrate that N6 neutralizes
approximately 80 percent of HIV
isolates which were resistant to other
antibodies of the same class, and does
so very potently. Its breadth and
potency makes N6 a highly desirable
candidate for development in
therapeutic or prophylactic strategies.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
National Institutes of Health
Potential Commercial Applications
[FR Doc. 2017–04807 Filed 3–10–17; 8:45 am]
BILLING CODE 4140–01–P
mstockstill on DSK3G9T082PROD with NOTICES
National Institutes of Health,
HHS.
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
SUMMARY:
VerDate Sep<11>2014
17:49 Mar 10, 2017
Jkt 241001
[FR Doc. 2017–04834 Filed 3–10–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
• Neutralized 98 percent of HIV
isolates tested.
• Neutralized 80 percent of HIV
isolates which were resistant to other
antibodies of the same class, and does
so very potently.
Development Stage: Pre-Clinical.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID; Investigator Initiated
Program Project Applications (P01).
Date: March 29, 2017.
Time: 11:00 a.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
• HIV therapeutic
• HIV prophylactic
Government-Owned Inventions;
Availability for Licensing
ACTION:
Dated: March 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
Competitive Advantages
Dated: March 7, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
AGENCY:
Inventors: Mark Connors, Jinghe
Huang, Byong Ha Kang, John Mascola,
Elise Ishida, Tongqing Zhou, Peter
Kwong, Anqi Zheng, all of NIAID.
Publications: Huang, Jinghe, et al.
‘‘Identification of a CD4-binding-site
antibody to HIV that evolved near-pan
neutralization breadth.’’ Immunity 45.5
(2016): 1108–1121.
Intellectual Property: HHS Reference
No. E–131–2015 et seq.—US provisional
application 62/136,228, US provisional
application 62/250,378, and PCT
application PCT/US2016/023145.
Licensing Contact: Chris Kornak, 240–
627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office (TTIPO) is
seeking parties interested in
collaborative research to further codevelop this technology. For
collaboration opportunities, please
contact Chris Kornak, 240–627–3705,
chris.kornak@nih.gov.
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
E:\FR\FM\13MRN1.SGM
13MRN1
Agencies
[Federal Register Volume 82, Number 47 (Monday, March 13, 2017)]
[Notices]
[Page 13460]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04834]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the patent applications listed below may be obtained by communicating
with the indicated licensing contact at the Technology Transfer and
Intellectual Property Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required
to receive copies of unpublished patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
N6, A Novel, Broad, Highly Potent HIV-Specific Antibody
Description of Technology
The N6 antibody has evolved a unique mode of binding that depends
less on a variable area of the HIV envelope known as the V5 region and
focuses more on conserved regions, which change relatively little among
HIV strains. This allows N6 to tolerate changes in the HIV envelope,
including the attachment of sugars in the V5 region, a major mechanism
by which HIV develops resistance to other VRC01-class antibodies. N6
was shown in pre-clinical studies to neutralize approximately 98
percent of HIV isolates tested. The studies also demonstrate that N6
neutralizes approximately 80 percent of HIV isolates which were
resistant to other antibodies of the same class, and does so very
potently. Its breadth and potency makes N6 a highly desirable candidate
for development in therapeutic or prophylactic strategies.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
HIV therapeutic
HIV prophylactic
Competitive Advantages
Neutralized 98 percent of HIV isolates tested.
Neutralized 80 percent of HIV isolates which were
resistant to other antibodies of the same class, and does so very
potently.
Development Stage: Pre-Clinical.
Inventors: Mark Connors, Jinghe Huang, Byong Ha Kang, John Mascola,
Elise Ishida, Tongqing Zhou, Peter Kwong, Anqi Zheng, all of NIAID.
Publications: Huang, Jinghe, et al. ``Identification of a CD4-
binding-site antibody to HIV that evolved near-pan neutralization
breadth.'' Immunity 45.5 (2016): 1108-1121.
Intellectual Property: HHS Reference No. E-131-2015 et seq.--US
provisional application 62/136,228, US provisional application 62/
250,378, and PCT application PCT/US2016/023145.
Licensing Contact: Chris Kornak, 240-627-3705,
chris.kornak@nih.gov.
Collaborative Research Opportunity: The Technology Transfer and
Intellectual Property Office (TTIPO) is seeking parties interested in
collaborative research to further co-develop this technology. For
collaboration opportunities, please contact Chris Kornak, 240-627-3705,
chris.kornak@nih.gov.
Dated: March 3, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04834 Filed 3-10-17; 8:45 am]
BILLING CODE 4140-01-P